Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 09, 2023 07:00 ET | Source: PolyPid Ltd.

PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023

PETACH TIKVA, Israel, Oct. 09, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
October 04, 2023 07:00 ET | Source: PolyPid Ltd.

PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology Platform

Safety Profile of D-PLEX100 and PLEX Platform Shown in Juvenile Animals for the First Time Results Could Support Clinical Evaluation of D-PLEX100 in Pediatric Population PETACH TIKVA, Israel, Oct. ...
September 22, 2023 07:00 ET | Source: PolyPid Ltd.

PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

PETACH TIKVA, Israel, Sept. 22, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
September 21, 2023 07:34 ET | Source: PolyPid Ltd.

PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health

PETACH TIKVA, Israel, Sept. 21, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced...
September 20, 2023 09:15 ET | Source: PolyPid Ltd.

PolyPid Announces Reverse Share Split

PETACH TIKVA, Israel, Sept. 20, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
September 19, 2023 07:00 ET | Source: PolyPid Ltd.

PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX₁₀₀

Company has Successfully Completed the Production of Three Process Validation Batches at Commercial Scale Completes a Substantial Requirement Toward the Planned Submission of D-PLEX100 NDA and MAA...
August 09, 2023 07:00 ET | Source: PolyPid Ltd.

PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Reached Agreement with U.S. FDA on Design of SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Resumed Recruitment into SHIELD II Phase...
July 26, 2023 07:00 ET | Source: PolyPid Ltd.

PolyPid to Report Second Quarter 2023 Financial Results and Operational Highlights on August 9, 2023

PETACH TIKVA, Israel, July 26, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced...
June 29, 2023 08:00 ET | Source: PolyPid Ltd.

PolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEX₁₀₀ against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections

Potent Antibacterial Efficacy of D-PLEX100 in In-vivo and Phase 2 Clinical Studies against a Wide Range of Bacteria Tested, including Resistant Strains D-PLEX100 Antibacterial Activity Attributed to...
June 22, 2023 07:00 ET | Source: PolyPid Ltd.

PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections

Company Recently Reached Agreement with FDA on Design of Trial Top-line Results Expected in Mid-2024 PETACH TIKVA, Israel, June 22, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq:...